Trials in Washington.
43 APOE4-relevant Alzheimer’s trials run in Washington — 21 of them recruiting. Each one translated into plain English, with our read on what it means for an APOE4 carrier.
- Built exclusively for APOE 4/4 carriersNCT02565511A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
This trial tested two investigational drugs, CAD106 (a vaccine-like immunotherapy targeting amyloid) and CNP520 (a small molecule targeting amyloid…
- Built specifically for APOE4 carriersNCT03131453A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
This trial tested CNP520, a drug designed to reduce amyloid buildup in the brain, against a placebo in cognitively normal older adults at elevated risk for…
- Open to carriers, but ARIA risk elevatedNCT03887455A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
This Phase 3 trial tests lecanemab, an intravenous and subcutaneous antibody drug, against placebo in people with early Alzheimer's disease — either mild…
- APOE4 carriers explicitly welcomedNCT04468659AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
This Phase 3 trial is testing lecanemab, an anti-amyloid antibody drug, in people who are cognitively normal but have early amyloid buildup in their brains —…
- Built exclusively for APOE4/4 carriersNCT04770220An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
This Phase 3 trial is testing ALZ-801, an oral drug designed to reduce toxic amyloid clusters in the brain, against a placebo in people with early Alzheimer's…
- APOE4 enrolled, response may differNCT00348140Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease
This Phase 3 trial tested rosiglitazone, a diabetes drug, as an add-on to standard Alzheimer's medications like Aricept in people with mild to moderate…
- Amyloid-focused, drug did not succeedNCT02008357Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
This Phase 3 trial tested solanezumab, an antibody drug given by IV infusion, in cognitively normal older adults who already had amyloid buildup in their…
- Heart trial, genotype not relevantNCT02884206Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction
This Phase 3 trial tested whether LCZ696 (sacubitril/valsartan, sold as Entresto) protects cognitive function better than valsartan alone in people with a…
- Observational only, no treatment involvedNCT02951598A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)
This study is not testing a treatment. It is an observational study tracking how people with early-stage Alzheimer's disease or MCI use health care, what that…
- Unrelated to APOE4 or Alzheimer'sNCT03047369The Myelin Disorders Biorepository Project
This is a biorepository project, not a treatment trial. Researchers are collecting medical records and biological samples (like blood or tissue) from people…
- Open to carriers, not 4-specificNCT03108846Escitalopram for Agitation in Alzheimer's Disease
This Phase 3 trial is testing whether escitalopram, a common antidepressant, can safely reduce agitation in people who already have Alzheimer's dementia. Phase…
- Not APOE4-related, movement disorder focusNCT03924414Trial of Parkinson's And Zoledronic Acid
This trial is testing whether a single IV infusion of zoledronic acid, a bone-strengthening drug already approved for osteoporosis, can reduce fractures in…
- Open to carriers, genotype not trackedNCT04098666Metformin in Alzheimer's Dementia Prevention
This trial is testing whether extended-release metformin, a widely used diabetes drug, can slow memory decline in people who are overweight and already showing…
- Open to carriers, not 4-specificNCT04148391NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)
This trial is testing NYX-458, an experimental oral drug, against a placebo in people who have mild cognitive impairment or mild dementia caused by Parkinson's…
- FTLD-focused, not APOE4-relevantNCT04363684ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
This is a large North American research registry and natural history study tracking people with frontotemporal lobar degeneration (FTLD) and related conditions…
- High ARIA risk for carriersNCT04437511A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
This Phase 3 trial tested donanemab, an anti-amyloid antibody drug, against placebo in people with early Alzheimer's disease. Researchers measured how well it…
- Directly recruits APOE4 carriersNCT04692441Apolipoprotein E (APOE) Genotype Effects on Triglycerides and Blood Flow in the Human Brain
This trial is testing whether a high-fat drink — specifically heavy cream — affects brain blood flow differently in people who carry the APOE4 gene versus…
- Observational only, genotype not specifiedNCT04916210Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY
The DISCOVERY study is an observational study — no drug or treatment is being tested. Researchers are following stroke survivors over time, collecting…
- Genetic study, carriers likely relevantNCT05010603Late Onset Alzheimer's Disease
This study collects blood samples and runs memory and thinking tests to look for genes that influence who gets Alzheimer's disease. It focuses on families…
- Detection study, genotype not relevantNCT05356702The Brain Health Study: A Pragmatic, Patient-Centered Trial
This trial is testing a screening tool called eRADAR, which uses existing electronic health records to flag patients in primary care who may have undetected…
- Open to carriers, not 4-specificNCT05399888A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age
This Phase 2 trial is testing BIIB080, a drug injected into the spinal fluid, to see whether it can slow cognitive decline in people with mild cognitive…
- Anti-amyloid drug — carriers face higher ARIA riskNCT05463731A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
This Phase 3 trial is testing remternetug, an anti-amyloid antibody given by IV or injection under the skin, in people with early symptomatic Alzheimer's…
- Familial mutation only, not APOE4NCT05552157A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
This Phase 2 trial is testing remternetug, an anti-amyloid antibody given by injection, in people who carry a rare genetic mutation (in APP, PSEN1, or PSEN2)…
- Not relevant to APOE4 or Alzheimer'sNCT05686551GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease
This trial is testing tominersen, a drug injected into the spinal fluid, against a placebo in people with prodromal or early Huntington's Disease. The goal is…
- ARIA-focused — carriers often restrictedNCT05738486A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
This Phase 3 trial is testing whether different dosing schedules of donanemab — an anti-amyloid antibody already conditionally approved — can reduce the rate…
- Late-stage AD only, genotype not relevantNCT05980949Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
This trial is testing whether KarXT, a drug targeting certain brain receptors, is safe to take for up to a year in people who already have Alzheimer's-related…
- Lifestyle study, genotype not requiredNCT06362824Promoting Physical Activity in Older Hispanic/Latino(a) Adults
This trial is testing a culturally adapted, fully remote physical activity program called De Pie y a Movernos, designed specifically for older Hispanic and…
- Care system study, not carrier-focusedNCT06397339Indian Transforming Alzheimer's Care Training (INTACT)
This trial tests a training program called INTACT, designed to help primary care clinics do a better job detecting and managing Alzheimer's and mild cognitive…
- Lifestyle study, genotype not requiredNCT06411561A Multi-Modal Combination Intervention to Promote Cognitive Function in Older Intensive Care Unit Survivors
This trial tests whether combining sleep improvement strategies with cognitive training helps older adults avoid mental decline after a stay in the ICU.…
- Unrelated to APOE4 or dementiaNCT06516965A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
This Phase 3 trial is testing povorcitinib, a JAK inhibitor pill, against a placebo in people with prurigo nodularis — a chronic skin condition causing intense…
- Open to carriers, not 4-specificNCT06585787A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
This trial is testing KarXT, an already-FDA-approved antipsychotic drug, as a treatment for hallucinations and delusions that sometimes develop in people who…
- Open to carriers, not 4-specificNCT06601933Cognitive Training and Neuroplasticity in Mild Cognitive Impairment: COGIT-2 Trial
This trial is testing whether doing crossword puzzles frequently (4 times a week) improves cognition and daily functioning better than doing them rarely (once…
- Unrelated to APOE4 or Alzheimer'sNCT06667414Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers
This study is mapping specific genetic markers called SNPs in people who carry the Huntington's disease gene mutation. Participants give a blood sample and…
- Open to carriers, not 4-specificNCT06721156A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)
This trial is testing MK-1167, an experimental drug given alongside a standard Alzheimer's medication called an acetylcholinesterase inhibitor. Researchers…
- Open to carriers, not 4-specificNCT06847321Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
This Phase 2 trial is testing LHP588, an oral capsule taken once daily, in people with mild to moderate Alzheimer's disease who also test positive for P.…
- Caregiving research, genotype irrelevantNCT06922188Development of Measures to Screen for Financial Hardship in Alzheimer's Disease and Dementia
This is not a treatment trial. Researchers are building new survey tools to measure financial hardship in people living with Alzheimer's and their caregivers.…
- Symptom trial, genotype not addressedNCT06937229A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
This Phase 3 trial is testing two drug formulations — KarXT and KarX-EC, both containing the same active ingredient xanomeline — for long-term management of…
- Open to carriers, not 4-specificNCT06976203A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
MINDSET 2 is testing KarXT plus KarX-EC — a combination drug regimen that works on muscarinic receptors in the brain — to see whether it improves cognition in…
- Open to carriers, not 4-specificNCT07011732A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
This trial is testing two drug combinations — KarXT (xanomeline plus trospium) and KarX-EC — to see whether they reduce agitation in people with confirmed…
- Open to carriers, not 4-specificNCT07011745A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
This trial is testing KarXT plus a new extended-release version called KarX-EC — a non-opioid, non-antipsychotic drug combination — to see whether it reduces…
- Genotype not mentioned, proceed cautiouslyNCT07094516A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
This trial is testing VHB937, a biological drug, in people with early Alzheimer's disease — either mild cognitive impairment or mild AD confirmed by…
- Unrelated to APOE4 or Alzheimer'sNCT07326709A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
This trial is testing votoplam, an oral drug designed to slow the progression of early-stage Huntington's disease. Researchers are comparing it against a…
- Caregiver trial, no APOE4 relevanceNCT07637097VOCALE LBD: Online Peer Support for Caregivers of People With Lewy Body Dementia
This trial tests whether an online peer support program called VOCALE LBD helps reduce depression in family caregivers of people with Lewy Body Dementia.…
Copy a forum-ready post
Keep exploring
Educational, not medical advice. Trial decisions belong between you and your physician.